Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-8040 + IST in AA and Hypoplastic MDS
NCT02462252Phase 2Completed
- Sponsor
- BioLineRx Ltd.
- Start
- Oct 2015
- Primary completion
- Nov 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of motixafortide in aplastic anemia, hypoplastic myelodysplastic syndrome (hMDS), sponsored by BioLineRx Ltd.. Started Oct 2015; status: completed.
02
Drugs
motixafortide
03
Conditions
aplastic anemiahypoplastic myelodysplastic syndrome (hMDS)
Beyond the preview
Go deeper on NCT02462252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02462252.